AES President Emeritus Dr. Elson So covered discussing SUDEP with your patients & their families and reviewed current and future research highlights.
Epilepsy and Seizure
Up to 45% of stroke victims over the age of 60 will develop epilepsy. Researchers at AES 2016 presented risk factors of post-stroke epilepsy.
From surgical procedure selection to multiscale imaging to use of the latest drugs, we present a list of 10 not-to-be-missed sessions at AES 2016.
November news includes potential Alzheimer treatments, FDA approval of a device to prevent recurrent stroke, & a newly typified headache disorder.
Researchers evaluated cognitive and motor development, receptive language, and memory in 214 children who had experienced febrile status epilepticus.
Although tremendous advances in research and medical ethics have been made since the mid-20th century, questions continue.
Oct. news includes an approved deep brain stimulation system for movement disorders & biomarkers that improve risk assessment in atrial fibrillation.
To investigate an association between epilepsy and autoimmune disease, researchers reviewed 25 studies, covering patients of various ages.
Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.
Little evidence exists to guide drug choice in elderly patients with epilepsy. The KOMET study compared carbamazepine, levitiracetam, and valproate.